Acute myeloid leukemia with t(9;11)(p22;q23)

Acute myeloid leukemia with t(9;11)(p22;q23), also known as AML with KMT2A-MLLT3 rearrangement, is a specific type of blood cancer. In this disease, the bone marrow (the spongy tissue inside your bones that makes blood cells) starts producing too many immature white blood cells called myeloid blasts. These abnormal cells crowd out healthy blood cells, leading to problems like infections, anemia, and bleeding. The name refers to a specific genetic change where pieces of chromosomes 9 and 11 swap places (called a translocation), creating an abnormal fusion gene that drives the cancer. This subtype is recognized by the World Health Organization as a distinct form of AML because it behaves differently from other types. Symptoms often come on quickly and can include fatigue, frequent infections, easy bruising or bleeding, fevers, and bone pain. Some patients may notice swollen gums or skin changes. This subtype is more common in children than adults and is generally considered to have an intermediate prognosis compared to other AML subtypes. Treatment typically involves intensive chemotherapy given in phases: induction therapy to achieve remission, followed by consolidation therapy to prevent relapse. In some cases, a bone marrow (stem cell) transplant may be recommended, especially if the leukemia comes back or is considered higher risk. Newer targeted therapies and clinical trials are also being explored. With modern treatment, many patients—especially children—can achieve long-term remission, though the journey is often challenging and requires close medical follow-up.

Bring these to your next appointment

• Q1.What is the exact genetic profile of my leukemia, and how does the t(9;11) translocation affect my treatment plan?,What are the chances of achieving remission with the recommended chemotherapy, and what happens if the first treatment doesn't work?,Will I need a bone marrow transplant, and if so, when should we start looking for a donor?,Are there any clinical trials available for KMT2A-rearranged AML, such as menin inhibitor trials?,What are the short-term and long-term side effects of the proposed treatment?,How will treatment affect my fertility, and are there options to preserve fertility before starting?,What support services are available to help with the emotional, financial, and practical challenges of treatment?

Common questions about Acute myeloid leukemia with t(9;11)(p22;q23)